NASDAQ$AURA
Aura Biosciences Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Aura Biosciences reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.
Aura Biosciences reported a net loss of $19.7 million for the first quarter of 2024. As of March 31, 2024, the company's cash and cash equivalents and marketable securities totaled $202.9 million, which is expected to fund operations into the second half of 2026. Enrollment continues in the global Phase 3 CoMpass trial for choroidal melanoma, and early Phase 1 data from the bladder cancer trial is expected mid-2024.
- Enrollment continues in the global Phase 3 CoMpass trial for the treatment of small choroidal melanoma and indeterminate lesions.
- Aura expects early Phase 1 data from its bladder cancer trial in mid-2024.
- Cash and cash equivalents and marketable securities totaled $202.9 million as of March 31, 2024.
- Aura believes its current cash is sufficient to fund operations into the second half of 2026.
Headline financials
Revenue & EPS history
Aura Biosciences · Revenue · Quarterly
$0
Forward guidance
Aura Biosciences believes its current cash and cash equivalents and marketable securities are sufficient to fund its operations into the second half of 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q1 2024
+1.3%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-7.0%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+26.0%
Q3 2021
Best reaction
-8.9%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.1% | -5.5% | -24.3% | |
| Q3 2025 | -0.7% | -2.9% | +17.4% | |
| Q2 2025 | +4.2% | -3.6% | -11.0% | |
| Q1 2025 | +1.9% | -0.5% | +6.8% | |
| Q4 2024 | -6.7% | -15.5% | -23.2% | |
| Q3 2024 | -7.3% | -15.0% | -24.2% | |
| Q1 2024 | -1.1% | +1.9% | +1.6% | |
| Q4 2023 | +2.9% | +1.7% | -5.4% | |
| Q3 2023 | +4.5% | +8.6% | +18.9% | |
| Q2 2023 | -8.9% | -8.8% | -16.4% | |
| Q1 2023 | +0.5% | +7.3% | +22.4% | |
| Q4 2022 | -1.0% | -1.0% | -15.6% | |
| Q3 2022 | +10.1% | +16.4% | +4.4% | |
| Q2 2022 | -0.5% | -2.6% | -19.0% | |
| Q1 2022 | +4.9% | +8.1% | -4.5% | |
| Q2 2021 | -1.5% | +8.7% | -21.4% | |
| Q4 2021 | -1.5% | +8.7% | -21.4% | |
| Q3 2021 | +26.0% | -1.1% | -10.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro